Screener
BridgeBio Pharma BBIO Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Accrued compensation and benefits | 39,338 | 76,703 |
| Accrued research and development liabilities | 54,430 | 41,436 |
| Operating lease liabilities, current portion | 4,439 | 6,192 |
| Deferred revenue, current portion | 6,115 | 7,190 |
| 2027 Notes, net | 547,483 | — |
| Other current liabilities (2) | 135,509 | 120,222 |
| Total current liabilities | 816,372 | 287,971 |
| 2033 Notes, net | 619,631 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's deferred revenue?
- BridgeBio Pharma (BBIO) reported deferred revenue of $6.12M in Q1 2026.
- How has BridgeBio Pharma's deferred revenue changed year-over-year?
- BridgeBio Pharma's deferred revenue decreased by 65.1% year-over-year, from $17.51M to $6.12M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about BridgeBio Pharma's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude